Callio Therapeutics is a biotechnology company focused on developing multi-payload antibody-drug conjugate technology to enhance therapeutic outcomes for cancer patients. By overcoming the limitations of existing single-payload therapies, Callio aims to maximize the therapeutic benefits of its innovative programs.
Leadership & Board
Key Executives
CEO & Co-FounderPiers Ingram
CSO & Co-FounderJerome Boyd-Kirkup
CMONaomi Hunder
CBOAngele Maki
Current Number of Employees23
Current LinkedIn Followers4,511
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$187M
Total Amount Raised$187M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$187M
Latest Funding Amount$187M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Callio Therapeutics had 23 employees as of September 28, 2026. The number of employees increased by 1 (4.55%) week-over-week.
23Latest Employee Count
1(4.55%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Callio Therapeutics had 4,511 followers as of September 28, 2026. The number of followers increased by 24 (0.53%) week-over-week.
4,511Latest Followers Count
24(0.53%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.